Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lexeo Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LXEO
Nasdaq
8731
https://www.lexeotx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lexeo Therapeutics Inc
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
- Apr 22nd, 2024 11:30 am
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
- Apr 16th, 2024 11:30 am
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
- Mar 13th, 2024 8:22 pm
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Mar 11th, 2024 11:42 am
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
- Mar 11th, 2024 11:30 am
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
- Feb 5th, 2024 12:00 pm
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:00 pm
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
- Dec 18th, 2023 12:00 pm
Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs
- Dec 13th, 2023 9:59 am
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
- Dec 11th, 2023 12:00 pm
J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential
- Nov 30th, 2023 1:42 pm
Scroll